ModernaInc.’s(mRNA) shares were up slightly at the previous close and kept the pre-market session trend today. The Company has gained 21.53% over the past week, 16.56% over the past month, and 45.43% so far this year.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Company’s Vaccine
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
mRNA-1273 is an mRNA vaccine in development for COVID-19 that encodes a prefusion-stabilized version of the Spike protein. It was created by Moderna and researchers from the National Institute of Allergy and Infectious Diseases (NIAID).
Read More
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
The latest News
A new supply update, provided by Moderna, Inc. (NASDAQ: MRNA), shows that 30.4 million doses have been supplied to the U.S. Government to date. Besides giving regular updates on supply and production, The Company continues to work closely with the U.S. Government. Approximately 10.1 million doses have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention1.
TheCompany confirms that it is on track to deliver to the United States government 100 million doses by the end of the first quarter of 2021, with an additional 200 million doses available by the quarter’s end. Moderna’s dedicated supply chain in the U.S. provides all U.S. products. The Company announced on January 4 that it had increased its projection for 2021 production from 500 to 600 million doses. To build up to a potential 1 billion dose capacity by 2021, Moderna continues to invest and add staff.
In December 2020, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization for the Moderna COVID-19 Vaccine. Moderna began supplying its vaccine to the government soon after. With an option to purchase 300 million additional doses of Moderna COVID-19 Vaccine, the U.S. Government has agreed to buy 200 million doses.
mRNA-1273 is an mRNA vaccine in development for COVID-19 that encodes a prefusion-stabilized version of the Spike protein. It was created by Moderna and researchers from the National Institute of Allergy and Infectious Diseases (NIAID).
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Conclusion
Experts estimate that MRNA’s stock price might increase by 17.88%. In conclusion, $185.00 was set as the high price target price for the shares to achieve during the next 12 months. Furthermore, analysts expect traders to maintain the price at a minimum of $69.00. A gain of -121.19 % is possible if that happens. The overall cost of MRNA this year has increased by 45.43%.
